Cancer research is one of the most exciting and demanding industries on earth. There is a lot of time, money and stress that goes into every cancer fighting product that’s being produced. If you don’t have the fortitude and perseverance, this industry isn’t for you. On the other hand, Seattle Genetics is thriving under these dire conditions. Located in Bothell, Washington, this biotech company has changed the game thanks to its revolutionary antibody-based therapies. These therapies are broken down into antibody-drug conjugates, and they are some of the best-selling cancer fighting medications on the market. Dr. Clay Siegall is in control of this ship, and he is one of the most well-respected individuals in the business.
Siegall has a new challenge on his hands. He wants to expand the company’s business practices by controlling its very own marketing. This may sound simple, but it’s truly not. By controlling the company’s marketing on an international level and by controlling the rights of the medications, Seattle Genetics wouldn’t have to share its hard-earned profits with other steakholders. Siegall has thoroughly studied international marketing, and he has first-hand knowledge of global markets thanks to his partnership with Takeda Oncology. By opening an office is Switzerland, he has taken the first step that is required to play ball in this large arena. Seattle Genetics is one of the leading oncology organizations in the world today. Developing and commercializing advanced cancer fighting therapies is the name of the game, and it has been doing so for quite some time.
Siegall is an accomplished doctor and an accomplished scientist. He co-founded this biotech company in 1998, and it has steadily grown over the years. Siegall’s principles include rigorous research, drug development and scientific innovation. The company thoroughly tests its drugs before they ever hit the market and there are at least 20 newer drugs in its pipeline of success. The company’s ADCETRIS drug is one of the most successful cancer fighting drugs of all-time. By securing multiple strategic licensing deals, ADCETRIS is now being used in up to 65 different countries. As of this year, the drug has brought in over $350 million. Dr. Clay Siegall and Seattle Genetics is the perfect combination to get things done efficiently, but only time will tell for the success of the company’s future international marketing campaign.